Form 4: Director Nancy Whiting Receives Stock Options at Boundless

Boundless Bio, Inc. director Nancy Whiting was granted 32,000 stock options as part of her compensation package.

Summary

• Director Nancy Whiting received a grant of 32,000 stock options on June 15, 2026.
• The options have an exercise price of $1.40 per share.
• The options are set to expire on June 14, 2036.
• Vesting occurs in equal monthly installments over 12 months, subject to continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the company's operational outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon the director's continued service on the board.

Future Outlook

The options vest over a 12-month period, incentivizing the director's continued tenure through mid-2027.

Industry Context

StockSavvy.ai notes that equity grants for non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for small-cap biotech firms.
• The 12-month vesting schedule is a common retention mechanism for board members in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options in monthly installments over the next year.

Key Dates

Keywords

Boundless Bio, BOLD, Director Compensation, Stock Options, Insider Transaction, SEC Form 4